suPAR is a potential biomarker for triage of patients with COVID-19 symptoms in the ED
Tue Mar 30 2021
Soluble urokinase plasminogen activator receptor as a decision marker for early discharge of patients with COVID-19 symptoms in the emergency department
published in The Journal of Emergency Medicine
A newly published paper written ED doctors shows that suPAR is a potential biomarker for triage and safe early discharge of patients with COVID-19 symptoms in the ED. suPAR can even be used even before SARS-CoV-2 status is known.
SARS-CoV-2 strains healthcare capacity. Better risk stratification, with discharge of patients with a predicted mild disease trajectory, can ease this burden. Elevated suPAR has previously been shown associated with risk of intubation in confirmed COVID-19 patients.
386 patients were included strengthening the paper’s COVID-19 conclusions, as well as the notion that suPAR is a biomarker that can help ED physicians decide whether a patient should be admitted or, in fact, can safely be discharged.
This helps reducing crowding in the ED and may thus allow overburdened COVID-19 staff across our hospitals to get a five-min break during their current COVID-19 24/7 schedules.
suPAR is a potential biomarker for triage and safe early discharge of patients with COVID-19 symptoms in the ED.
– Stauning et al, Journal of Emergency Medicine, March 2021
